Trial review
SURMOUNT-4: Weight Maintenance and Tirzepatide Withdrawal
SURMOUNT-4 is the withdrawal trial, and it is the one that changes the arithmetic of treatment. After a 36-week open-label lead-in, 670 participants were randomised to continue tirzepatide or switch to placebo for 52 weeks. Those continuing lost a further 5.5%. Those withdrawn regained 14.0%.
The design, and why it answers a different question
Most obesity trials ask how much weight comes off. SURMOUNT-4 asked what happens when you stop, which is the more consequential question for anyone deciding what to spend.
All 670 participants took tirzepatide openly for 36 weeks. They were then randomised either to continue or to switch to placebo for a further 52 weeks. Over that period the continuing group lost a further 5.5% of body weight; the withdrawn group regained 14.0%.
What it means clinically
It is consistent with obesity understood as a chronic condition: the treatment manages it while present, and the effect does not persist after withdrawal. That is unremarkable for chronic disease medicine — nobody expects blood pressure to stay controlled after stopping an antihypertensive — but it collides with how weight-loss treatment is usually sold, as a course with an endpoint.
Two limitations that matter
Both arms are a responder population. Everyone completed a 36-week lead-in, so everyone in the trial tolerated the drug and responded to it. The regain figure describes what happens to people for whom the treatment worked, which is not the same as what happens to everyone prescribed it.
It tested abrupt withdrawal to placebo. Tapering strategies were not studied, and neither was maintenance at a reduced dose. Anyone telling you a taper avoids regain is extrapolating beyond this evidence — including the microdose programmes that market themselves as maintenance.
What it means financially
This is the part almost no pricing page mentions. If maintaining the result requires maintaining the medication, the figure that matters is not the introductory rate and not the annual cost. It is the indefinite monthly cost at a maintenance dose.
Over five years, the gap between a flat-rate compounded plan at $186 and a brand maintenance tier at $449 is roughly $15,800. Over the same period, the difference between the cheapest FDA-approved oral at $149 and a $349 compounded programme is about $12,000. Those are the numbers a first-month discount is distracting from.
It also reframes prepayment. A twelve-month commitment lowers the monthly figure and raises the amount at risk. For a treatment likely to continue indefinitely that may be a reasonable trade — but it should be made knowing that stopping is followed by substantial regain.
Source
Aronne LJ et al., JAMA 2024. ClinicalTrials.gov NCT04660643. Funded by Eli Lilly.
| Design | Phase 3 randomised withdrawal trial |
|---|---|
| Population | Adults with obesity who completed an open-label tirzepatide lead-in |
| Sample size | 670 randomised |
| Intervention | not captured |
| Comparator | Placebo, after withdrawal |
| Duration | 88 weeks total, 36-week open-label lead-in then 52-week randomised withdrawal |
| Primary endpoint | Percentage change in body weight during the randomised withdrawal period |
| Main result | Participants who continued lost a further 5.5%. Participants withdrawn to placebo regained 14.0% |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Who was eligible | Adults with obesity who completed an open-label tirzepatide lead-in |
| 2 | What they received | Not captured — intervention and dose pending. |
| 3 | What it was compared against | Placebo, after withdrawal |
| 4 | For how long | 88 weeks total, 36-week open-label lead-in then 52-week randomised withdrawal |
| 5 | What was measured first | Percentage change in body weight during the randomised withdrawal period |
| 6 | What the group average was | Participants who continued lost a further 5.5%. Participants withdrawn to placebo regained 14.0% |
| 7 | What it does not tell you | A group average is not a prediction for any individual reader. |
Show this figure as a table
| Item | Weight change | Evidence |
|---|---|---|
| Continued tirzepatide, further loss | 6% | Verified |
| Withdrawn to placebo, regain | 14% | Verified |
| Question | Position |
|---|---|
| Average effect in the studied population | Reported above Verified |
| Your individual outcome | Not predicted by any trial |
| Effect of a compounded preparation | Not studied — this was an approved product |
| Effect at doses outside the protocol | Not studied |
| Effect after stopping | Only SURMOUNT-4 tested withdrawal |
| Long-term safety beyond the window | Outside the observation period |
Questions readers actually ask
Will I regain weight if I stop?
Participants withdrawn to placebo regained 14.0% of body weight over 52 weeks, while those continuing lost a further 5.5%. Individual outcomes vary.
Does tapering prevent regain?
Unknown. The trial tested abrupt withdrawal to placebo. Tapering and reduced-dose maintenance were not studied.
How should this change which provider I choose?
It makes the indefinite monthly price at a maintenance dose the figure to compare, rather than an introductory rate or a first-year total.
Related on this site
- Research hubResearch
- SURMOUNT-1 Tirzepatide Trial ExplainedResearch
- SURMOUNT-3 Tirzepatide Trial ExplainedResearch
- SURMOUNT-5: Tirzepatide vs Semaglutide Head to HeadResearch
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Tirzepatide Clinical Trial FinderTools
- SURPASS-2: Tirzepatide vs Semaglutide in Type 2 DiabetesResearch
- SURMOUNT-OSA and Tirzepatide for Sleep ApneaResearch
GLP-1 Tirzepatide Review. “SURMOUNT-4: Weight Maintenance and Tirzepatide Withdrawal.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/research/surmount-4/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.